Factors predicting the recurrence of Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis in children after treatment using the HLH-2004 protocol

Ryu Yanagaisawa, Kazuyuki Matsuda, Shoichi Ohga, Hirokazu Kanegane, Akira Morimoto, Yasuhiro Okamoto, Akira Ohara, Keitaro Fukushima, Manabu Sotomatsu, Keiko Nomura, Akiko M. Saito, Keizo Horibe, Eiichi Ishii, Yozo Nakazawa

Research output: Contribution to journalArticle

Abstract

Epstein–Barr virus (EBV)-associated hemophagocytic lymphohistiocytosis (HLH) is highly prevalent in Japan. To date, no standard treatment for EBV–HLH has been established owing to the diversity in treatment response and the difficulty in assessing prognostic factors. The present prospective study recruited 27 children with EBV–HLH who were also part of the HLH-2004 study. EBV load in the peripheral blood was monitored at diagnosis and 2, 4, and 8 weeks after treatment initiation. Additionally, T-cell receptor (TCR) clonality and other laboratory data were evaluated. TCR clonality was positive in 14 patients at diagnosis. Seven of 27 patients experienced recurrences after treatment. No correlation was noted among any clinical data at diagnosis of patients with and without recurrence. However, the recurrence rate was significantly higher in patients aged < 2 years and/or those with a high plasma EBV load of > 10 3 copies/mL 2 weeks after treatment than that in patients without these factors. These findings suggest that a younger age or a high EBV load in plasma at the early phase of treatment is a factor predicting a recurrence and helps guide the intensity of subsequent treatment phases for children with EBV–HLH.

Original languageEnglish
Pages (from-to)612-617
Number of pages6
JournalInternational journal of hematology
Volume109
Issue number5
DOIs
Publication statusPublished - May 3 2019

Fingerprint

Hemophagocytic Lymphohistiocytosis
Viruses
Recurrence
T-Cell Antigen Receptor
Therapeutics
Japan
Prospective Studies

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Factors predicting the recurrence of Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis in children after treatment using the HLH-2004 protocol. / Yanagaisawa, Ryu; Matsuda, Kazuyuki; Ohga, Shoichi; Kanegane, Hirokazu; Morimoto, Akira; Okamoto, Yasuhiro; Ohara, Akira; Fukushima, Keitaro; Sotomatsu, Manabu; Nomura, Keiko; Saito, Akiko M.; Horibe, Keizo; Ishii, Eiichi; Nakazawa, Yozo.

In: International journal of hematology, Vol. 109, No. 5, 03.05.2019, p. 612-617.

Research output: Contribution to journalArticle

Yanagaisawa, R, Matsuda, K, Ohga, S, Kanegane, H, Morimoto, A, Okamoto, Y, Ohara, A, Fukushima, K, Sotomatsu, M, Nomura, K, Saito, AM, Horibe, K, Ishii, E & Nakazawa, Y 2019, 'Factors predicting the recurrence of Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis in children after treatment using the HLH-2004 protocol', International journal of hematology, vol. 109, no. 5, pp. 612-617. https://doi.org/10.1007/s12185-019-02612-2
Yanagaisawa, Ryu ; Matsuda, Kazuyuki ; Ohga, Shoichi ; Kanegane, Hirokazu ; Morimoto, Akira ; Okamoto, Yasuhiro ; Ohara, Akira ; Fukushima, Keitaro ; Sotomatsu, Manabu ; Nomura, Keiko ; Saito, Akiko M. ; Horibe, Keizo ; Ishii, Eiichi ; Nakazawa, Yozo. / Factors predicting the recurrence of Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis in children after treatment using the HLH-2004 protocol. In: International journal of hematology. 2019 ; Vol. 109, No. 5. pp. 612-617.
@article{8c590611e682468b8e600b4ffe08a6b1,
title = "Factors predicting the recurrence of Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis in children after treatment using the HLH-2004 protocol",
abstract = "Epstein–Barr virus (EBV)-associated hemophagocytic lymphohistiocytosis (HLH) is highly prevalent in Japan. To date, no standard treatment for EBV–HLH has been established owing to the diversity in treatment response and the difficulty in assessing prognostic factors. The present prospective study recruited 27 children with EBV–HLH who were also part of the HLH-2004 study. EBV load in the peripheral blood was monitored at diagnosis and 2, 4, and 8 weeks after treatment initiation. Additionally, T-cell receptor (TCR) clonality and other laboratory data were evaluated. TCR clonality was positive in 14 patients at diagnosis. Seven of 27 patients experienced recurrences after treatment. No correlation was noted among any clinical data at diagnosis of patients with and without recurrence. However, the recurrence rate was significantly higher in patients aged < 2 years and/or those with a high plasma EBV load of > 10 3 copies/mL 2 weeks after treatment than that in patients without these factors. These findings suggest that a younger age or a high EBV load in plasma at the early phase of treatment is a factor predicting a recurrence and helps guide the intensity of subsequent treatment phases for children with EBV–HLH.",
author = "Ryu Yanagaisawa and Kazuyuki Matsuda and Shoichi Ohga and Hirokazu Kanegane and Akira Morimoto and Yasuhiro Okamoto and Akira Ohara and Keitaro Fukushima and Manabu Sotomatsu and Keiko Nomura and Saito, {Akiko M.} and Keizo Horibe and Eiichi Ishii and Yozo Nakazawa",
year = "2019",
month = "5",
day = "3",
doi = "10.1007/s12185-019-02612-2",
language = "English",
volume = "109",
pages = "612--617",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "5",

}

TY - JOUR

T1 - Factors predicting the recurrence of Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis in children after treatment using the HLH-2004 protocol

AU - Yanagaisawa, Ryu

AU - Matsuda, Kazuyuki

AU - Ohga, Shoichi

AU - Kanegane, Hirokazu

AU - Morimoto, Akira

AU - Okamoto, Yasuhiro

AU - Ohara, Akira

AU - Fukushima, Keitaro

AU - Sotomatsu, Manabu

AU - Nomura, Keiko

AU - Saito, Akiko M.

AU - Horibe, Keizo

AU - Ishii, Eiichi

AU - Nakazawa, Yozo

PY - 2019/5/3

Y1 - 2019/5/3

N2 - Epstein–Barr virus (EBV)-associated hemophagocytic lymphohistiocytosis (HLH) is highly prevalent in Japan. To date, no standard treatment for EBV–HLH has been established owing to the diversity in treatment response and the difficulty in assessing prognostic factors. The present prospective study recruited 27 children with EBV–HLH who were also part of the HLH-2004 study. EBV load in the peripheral blood was monitored at diagnosis and 2, 4, and 8 weeks after treatment initiation. Additionally, T-cell receptor (TCR) clonality and other laboratory data were evaluated. TCR clonality was positive in 14 patients at diagnosis. Seven of 27 patients experienced recurrences after treatment. No correlation was noted among any clinical data at diagnosis of patients with and without recurrence. However, the recurrence rate was significantly higher in patients aged < 2 years and/or those with a high plasma EBV load of > 10 3 copies/mL 2 weeks after treatment than that in patients without these factors. These findings suggest that a younger age or a high EBV load in plasma at the early phase of treatment is a factor predicting a recurrence and helps guide the intensity of subsequent treatment phases for children with EBV–HLH.

AB - Epstein–Barr virus (EBV)-associated hemophagocytic lymphohistiocytosis (HLH) is highly prevalent in Japan. To date, no standard treatment for EBV–HLH has been established owing to the diversity in treatment response and the difficulty in assessing prognostic factors. The present prospective study recruited 27 children with EBV–HLH who were also part of the HLH-2004 study. EBV load in the peripheral blood was monitored at diagnosis and 2, 4, and 8 weeks after treatment initiation. Additionally, T-cell receptor (TCR) clonality and other laboratory data were evaluated. TCR clonality was positive in 14 patients at diagnosis. Seven of 27 patients experienced recurrences after treatment. No correlation was noted among any clinical data at diagnosis of patients with and without recurrence. However, the recurrence rate was significantly higher in patients aged < 2 years and/or those with a high plasma EBV load of > 10 3 copies/mL 2 weeks after treatment than that in patients without these factors. These findings suggest that a younger age or a high EBV load in plasma at the early phase of treatment is a factor predicting a recurrence and helps guide the intensity of subsequent treatment phases for children with EBV–HLH.

UR - http://www.scopus.com/inward/record.url?scp=85064620881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064620881&partnerID=8YFLogxK

U2 - 10.1007/s12185-019-02612-2

DO - 10.1007/s12185-019-02612-2

M3 - Article

VL - 109

SP - 612

EP - 617

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 5

ER -